In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...

Ulta Beauty ( ULTA) was the best-performing stock in the S&P 500 after the beauty products retailer beat profit and sales ...

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 4.9% over the past month. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance.

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 8.5% over the past three ... Overall, we are quite pleased with Regeneron Pharmaceuticals' performance. In particular, it's great to see ...

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 4.9% over the past month. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s ...

In 2021, Regeneron earned $5.8bn ... relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results.

Regeneron has consistently proven its ability to innovate and deliver solid financial results and excellent stock market performance. The company's basic playbook hasn't changed, and in my view ...